Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Johnson & Johnson said on Tuesday it would buy medical device maker V-Wave in a deal potentially worth up to $1.1 billion, marking the latest acquisition to bolster its devices unit.

J&J to buy medical device maker V-Wave in up to $1.1 bln deal

SPDR Gold Trust

NextEra Energy

Procter & Gamble

The stock market is dynamic, often characterized by periods of volatility and uncertainty. These periods can be particularly challenging for investors susceptible to the pervasive influence of Fear, Uncertainty, and Doubt (FUD).

4 Defensive Stocks to Combat Market Fear, Uncertainty, and Doubt

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson1 (NYSE: JNJ) today announced that it has entered into a definitive agreement to acquire V-Wave Ltd., a privately-held company focused on developing innovative treatment options for patients with heart failure. Under the terms of the agreement, Johnson & Johnson will acquire V-Wave for an upfront payment of $600 million, subject to customary adjustments, with the potential for additional regulatory and commercial milestone payments.

Johnson & Johnson to Acquire V-Wave

The U.S. Food and Drug Administration on Tuesday approved Johnson & Johnson's chemotherapy-free combination therapy for patients with a type of non-small cell lung cancer.

US FDA approves J&J's combination therapy for type of lung cancer

Johnson & Johnson JNJ, +0.15% said Tuesday the U.S. Food and Drug Administration has approved a combination treatment for a type of lung cancer that's the first chemotherapy-free regimen. The FDA has approved the combination of Rybrevant plus Lazcluze for first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer, or NSCLC, with epidermal growth factor receptor exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test, the company said in a statement.

Johnson & Johnson wins first FDA approval for chemotherapy-free lung cancer treatment

RYBREVANT® plus LAZCLUZE™ is the first and only chemotherapy-free regimen showing superior progression-free survival versus osimertinib Following Priority Review, approval is based on Phase 3 MARIPOSA results showing RYBREVANT® plus LAZCLUZE™ reduced the risk of disease progression or death by 30 percent versus osimertinib, with a nine-month-longer median duration of response RARITAN, N.J. , Aug. 20, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) approved RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test.1,2 With this milestone, RYBREVANT® plus LAZCLUZE™ becomes the first and only multitargeted, chemotherapy-free combination regimen with demonstrated superiority versus osimertinib approved for the first-line treatment of patients with EGFR-mutated NSCLC.1,2 RYBREVANT® is an EGFR- and MET*-directed bispecific antibody that engages the immune system, and LAZCLUZE™ is a highly selective, brain-penetrant, third-generation oral EGFR TKI**.

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) approved in the U.S. as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancer

AstraZeneca

GlaxoSmithKline

Eli Lilly

Merck

Novo Nordisk

Novartis

Pfizer

Roche Holding AG

Sanofi

In the ever-evolving pharmaceutical landscape, financial stability and business resilience are crucial for long-term success. S&P Global, a leading financial information firm, recently released a comprehensive report evaluating the world's top pharmaceutical companies based on their business and financial risk profiles.

Top 10 pharmaceutical companies in 2024: S&P Global's latest ratings and rankings

Apple

Coca-Cola

Medtronic

Exxon Mobil

Dividend growth stocks often outperform other asset classes over long periods. These five blue-chip companies could form the basis of a rock-solid dividend growth portfolio.

5 Dividend Growth Stocks to Buy and Hold Forever

Amgen

The Dow Jones Industrial Average contains shares of 30 companies that lead their respective industries. Now that it no longer sells consumer goods, Johnson & Johnson's dividend growth rate could shift into a higher gear.

2 Dow Jones Dividend Stocks With Above-Average Yields to Buy Now and Hold for at Least a Decade

Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock?

Why Is Johnson & Johnson (JNJ) Up 2.4% Since Last Earnings Report?

COLUMBIA, S.C.--(BUSINESS WIRE)--A South Carolina jury has sided with a cancer patient who sued pharmaceutical giant Johnson & Johnson (NYSE:JNJ) saying use of the company's iconic Baby Powder caused his lung cancer. Jurors awarded Michael Perry and his family $32.6 million in compensatory damages and another $30.7 million in punitive damages. Along with Johnson & Johnson, the jury also found co-defendant American International Industries negligent and liable in the case. Mr. Perry was.

South Carolina Jury Awards $63.4 Million to Johnson & Johnson Asbestos Victim

Health Care Select Sector SPDR Fund

Zoetis

Quality Snapshots evaluate dividend-growth companies based on five quality factors including financial performance, resilience and dividend safety. This healthcare sector overview identifies 26 top quality stocks in the sector. Johnson & Johnson and Zoetis discussed as high-quality, fairly valued healthcare stocks with very different yields and growth rates.

The Highest Quality Dividend-Growth Healthcare Stocks

24/7 Wall St. Insights Stocks that consistently raise their dividends offer investors huge total return potential.

Prediction: Johnson & Johnson's Dividend Payouts Will Increase in 2025

American Water Works

Brookfield Infrastructure Partners L.P.

Mondelez

Republic Services

J. M. Smucker

WEC Energy Group

Are you starting to get nervous about the frothy stock market and thinking about taking some profits off the table? You're not alone.

7 Recession-Resistant Stocks to Hold Onto for Dear Life in 2024

Johnson & Johnson is preparing to unveil widespread support in coming days for a $6.48 billion offer to settle tens of thousands of legal actions alleging its Baby Powder and other talc products caused cancer, two people familiar with the matter said.

J&J to disclose support for $6.5 billion talc settlement

Exclusive: J&J near disclosing support for talc settlement, sources say

British American Tobacco

Lowe's

McDonald's

Altria

From a long-term perspective, prolonged and stable returns often lead to dividend stocks. These types of stocks provide constant income and mark strong business fundamentals.

7 Dependable Dividend Stocks for Long-Term Income

NEWARK, N.J.--(BUSINESS WIRE)--The attorneys representing tens of thousands of women in their talc-related ovarian cancer lawsuits against Johnson & Johnson (NYSE:JNJ) are calling for passage of a measure in Congress that would end the ability of solvent companies to use the so-called Texas Two-Step bankruptcy process in order to avoid lawsuit liabilities. The process involves taking a company's liabilities – in this case, the thousands of talc-ovarian cancer lawsuits – placing them into a.

Lawyers for Ovarian Cancer Victims Endorse Proposed Texas Two-Step Remedy

Microsoft

Visa

Blue-chip stocks are commanding attention from investors looking for stability and reliability amidst a fluctuating market. Typically, these stock market stalwarts are known for their solid financials, long histories of profitability and consistent records of dividend payments.

3 Blue-Chip Stocks to Buy on the Dip: August 2024

Johnson & Johnson is reportedly nearing enough support to finalize a $6.5 billion settlement for lawsuits related to cancer cases linked to its baby powder and other talc products.

J&J has enough support from claimants for $6.5 billion talc settlement: report

Archer-Daniels-Midland Company

Amazon

NVIDIA

QUALCOMM

The world is shrouded in numerous uncertainties. S&P's macro outlook for the next 12 months is pessimistic, pointing to worsening trends in 4 out of 7 risk categories. Whether you are risk-averse or a risk-taker, you would do well to have a portion of your portfolio invested in companies that can let you sleep-well-at-night. I recommend a balanced approach to investing, including holding cash and investing in hard-to-go-bust companies with strong credit ratings, cash flows, and growth.

6 SWAN Stocks To Own

Johnson & Johnson has cleared a key threshold of support for its proposed $6.5 billion settlement of tens of thousands of lawsuits alleging its baby powder and other talc products caused cancer, according to a Bloomberg report.

News for Johnson & Johnson Stock (JNJ)